Follow-up on Ph-MRD responders. (A) Hematologic RFS of the 6 Ph⁻ MRD responders who received no further treatment after blinatumomab. The median follow-up was 30.2 months and the lower limit of the 95% confidence interval for median follow-up was 6.5 months. (B) Duration of MRD response of the 6 Ph⁻ MRD responders who received no further treatment after blinatumomab. The median follow-up was 29.2 months and the lower limit of the 95% confidence interval for median follow-up was 14.4 months.